Association between 4-benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it

Abstract

Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.

1 - A method of treating a condition selected from cognitive disturbances associated with cerebral aging and cognitive disturbances associated with neurodegenerative diseases in a subject in need thereof, comprising administration of a combination comprising 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): 
       
         
           
           
               
               
           
         
       
       or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. 
     
     
         2 - A method of treating a condition selected from cognitive disturbances associated with Alzheimer's disease and cognitive disturbances associated with Parkinson's disease in a subject in need thereof, comprising administration of a combination comprising 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): 
       
         
           
           
               
               
           
         
       
       or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. 
     
     
         3 - The method of  claim 2 , wherein the 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide is in the form of an oxalate or hydrochloride. 
     
     
         4 - The method of  claim 2 , wherein the condition is cognitive disturbances associated with Alzheimer's disease and the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof. 
     
     
         5 - The method of  claim 4 , wherein the acetylcholinesterase inhibitor is donepezil hydrochloride. 
     
     
         6 - The method of  claim 5 , wherein the 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide is administered in the form of a hydrochloride at a daily dose of 2 mg, 5 mg or 20 mg (expressed as base), and wherein the donepezil hydrochloride is administered at a daily dose of 10 mg. 
     
     
         7 - The method of  claim 2 , wherein the condition is cognitive disturbances associated with Parkinson's disease and the acetylcholinesterase inhibitor is rivastigmine or a pharmaceutically acceptable salt thereof. 
     
     
         8 - The method of  claim 7 , wherein the acetylcholinesterase inhibitor is rivastigmine hydrobromide.